PE84699A1 - Formula de vacuna polinucleotidica especialmente contra la patologia respiratoria de los bovinos - Google Patents

Formula de vacuna polinucleotidica especialmente contra la patologia respiratoria de los bovinos

Info

Publication number
PE84699A1
PE84699A1 PE1998000035A PE00003598A PE84699A1 PE 84699 A1 PE84699 A1 PE 84699A1 PE 1998000035 A PE1998000035 A PE 1998000035A PE 00003598 A PE00003598 A PE 00003598A PE 84699 A1 PE84699 A1 PE 84699A1
Authority
PE
Peru
Prior art keywords
vaccine
viruses
bovine
virus
polynucleotidic
Prior art date
Application number
PE1998000035A
Other languages
English (en)
Inventor
Michel Riviere
Philippe Baudu
Jean-Christophe Audonnet
Annabelle Bouchardon
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of PE84699A1 publication Critical patent/PE84699A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/813—Viral vaccine for bovine species, e.g. cattle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPRENDE DE 3-4 VALENCIAS DE VACUNA POLINUCLEOTIDA, CADA UNA DE LAS CUALES COMPRENDE UN PLASMIDO QUE EXPRESA IN VIVO EN LAS CELULAS HUESPED UN GEN DE UNA VALENCIA DE PATOGENIA RESPIRATORIA BOVINA. ESTAS VALENCIAS ESTAN ELEGIDAS DE HERPES VIRUS BOVINO, VIRUS RESPIRATORIO SINCITIAL BOVINO, VIRUS DE LA ENFERMEDAD DE LAS MUCOSAS, VIRUS PARAINFLUENZA DE TIPO 3. LOS PLASMIDOS PARA CADA VALENCIA COMPRENDE UNO O VARIOS GENES ELEGIDOS DE gB Y gD PARA EL VIRUS DE HERPES BOVINO (BHV), F Y G PARA EL VIRUS RESPIRATORIO SINCITIAL BOVINO, HN Y F PARA EL VIRUS PARAINFLUENZA DE TIPO 3, E2, C+E1+E2 Y E1+E2 PARA EL VIRUS DE LA ENFERMEDAD DE LAS MUCOSAS. LA DOSIS COMPRENDIDA DE ESTA VACUNA ES DE 10 ng A 1 mg. LA FORMULA DE LA VACUNA TAMBIEN PUEDE SER UTILIZADA COMO REFUERZO DE UNA PRIMERA VACUNA POLINUCLEOTIDICA ELEGIDA DE VACUNA ENTERA VIVA, VACUNA ENTERA INACTIVADA, VACUNA DE SUBUNIDAD, VACUNA RECOMBINANTE
PE1998000035A 1996-07-19 1998-01-16 Formula de vacuna polinucleotidica especialmente contra la patologia respiratoria de los bovinos PE84699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9609403A FR2751229B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins

Publications (1)

Publication Number Publication Date
PE84699A1 true PE84699A1 (es) 1999-11-28

Family

ID=9494497

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000035A PE84699A1 (es) 1996-07-19 1998-01-16 Formula de vacuna polinucleotidica especialmente contra la patologia respiratoria de los bovinos

Country Status (28)

Country Link
US (2) US6376473B1 (es)
EP (2) EP1382348B1 (es)
JP (1) JP2000516200A (es)
AP (1) AP9701044A0 (es)
AR (1) AR007862A1 (es)
AT (2) ATE307607T1 (es)
AU (1) AU734442B2 (es)
BR (1) BR9710506A (es)
CA (1) CA2260855C (es)
CO (1) CO4700306A1 (es)
CZ (2) CZ298898B6 (es)
DE (2) DE69734483T2 (es)
DK (2) DK0912194T3 (es)
ES (2) ES2254833T3 (es)
FR (1) FR2751229B1 (es)
HR (1) HRP970383A2 (es)
HU (2) HU228353B1 (es)
ID (1) ID19513A (es)
IL (2) IL127703A0 (es)
MA (1) MA24269A1 (es)
NZ (4) NZ517686A (es)
PE (1) PE84699A1 (es)
PL (1) PL190122B1 (es)
PT (1) PT912194E (es)
RU (1) RU2305560C2 (es)
UA (1) UA70914C2 (es)
WO (1) WO1998003200A2 (es)
ZA (1) ZA976283B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
US20050202484A1 (en) 2004-02-19 2005-09-15 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
WO2006115843A2 (en) 2005-04-25 2006-11-02 Merial Limited Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP3536704B1 (en) 2005-11-14 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
EP2147105B1 (en) 2007-05-02 2013-04-24 Merial Limited Dna plasmids having improved expression and stability
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
KR101715415B1 (ko) 2008-11-28 2017-03-10 메리얼 인코포레이티드 재조합 조류 인플루엔자 백신 및 그의 용도
DK2998315T4 (da) 2009-04-03 2022-02-07 Boehringer Ingelheim Animal Health Usa Inc Newcastle sygdomsvirus-bårne fuglevacciner
US10633667B2 (en) 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
JP5959440B2 (ja) 2010-01-19 2016-08-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 病原体の検出および治療のための改変オプソニン
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
RU2575599C2 (ru) 2010-03-12 2016-02-20 Мериал Лимитед Рекомбинантные вакцины против вируса "синего языка", их применение
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
AR084358A1 (es) * 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
AU2012240240A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
JP6407714B2 (ja) 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
CA2837582C (en) 2011-05-27 2021-03-02 Merial Limited Genetic vaccines against hendra virus and nipah virus
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
CA2844927C (en) 2011-08-12 2017-10-31 Merial Limited Vacuum-assisted preservation of biological products, in particular of vaccines
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
US20130177591A1 (en) 2012-01-10 2013-07-11 Merial Limited Lipid Based Adjuvants for DNA Plasmids
US9567606B2 (en) 2012-02-14 2017-02-14 Merial Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
HUE033858T2 (en) 2012-02-14 2018-01-29 Merial Inc Rotavirus unit vaccines and method for their preparation and use
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
CN104582724A (zh) 2012-06-13 2015-04-29 梅里亚有限公司 重配btv和ahsv疫苗
CA2879915C (en) 2012-08-01 2022-07-05 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
EP2968514A1 (en) 2013-03-12 2016-01-20 Merial, Inc. Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHODS AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR CAPTURE OF A TARGET ENTITY
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201890110A1 (ru) 2015-06-23 2018-05-31 Мериал, Инк. Рекомбинантные вирусные векторы, содержащие минорные белки prrsv, и способы их получения и применения
EP3331549B1 (en) 2015-08-06 2020-12-23 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
CN108135997A (zh) 2015-08-20 2018-06-08 梅里亚股份有限公司 Fcv重组疫苗及其用途
HRP20231630T1 (hr) 2015-09-29 2024-03-15 Boehringer Ingelheim Animal Health USA Inc. Cjepiva sa česticama nalik na virus (vlp) psećeg parvovirusa (cpv) i njihove uporabe
MA42640B1 (fr) 2015-11-23 2021-06-30 Merial Inc Protéines de fusion de dmdv et e2 et leurs utilisations
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN109021081B (zh) * 2018-08-10 2019-06-04 山东大学 一种牛病毒性腹泻病毒样颗粒及其构建方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU611784B2 (en) * 1988-04-22 1991-06-20 Pharmacia & Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
JPH05509231A (ja) * 1990-07-24 1993-12-22 ザ ユーエイビー リサーチ ファンデーション ウシｒｓウイルスの組換えｄｎａ、タンパク質ワクチン、抗体、および形質転換細胞の使用法
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
CA2136677A1 (en) * 1993-12-29 1995-06-30 Intervet, Inc. Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5541102A (en) * 1994-09-02 1996-07-30 Board Of Regents, University Of Nebraska-Lincoln Bovine cell line resistant to in vitro infection by bovine viral diarrhea virus and all other known pestiviruses
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6060457A (en) 1996-06-20 2000-05-09 Universite De Montreal DNA plasmid vaccine for immunization of animals against BVDV
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
JP5566663B2 (ja) * 2009-11-09 2014-08-06 三菱重工業株式会社 多翼遠心ファンおよびそれを用いた空気調和機

Also Published As

Publication number Publication date
BR9710506A (pt) 1999-08-17
EP1382348B1 (fr) 2005-10-26
DK0912194T3 (da) 2004-03-15
ES2254833T3 (es) 2006-06-16
AP9701044A0 (en) 1997-07-31
HU228353B1 (en) 2013-03-28
US20020160018A1 (en) 2002-10-31
JP2000516200A (ja) 2000-12-05
HU225169B1 (en) 2006-07-28
EP1382348A2 (fr) 2004-01-21
RU2002132831A (ru) 2005-01-20
DE69725988D1 (de) 2003-12-11
ZA976283B (en) 1999-01-19
DE69725988T2 (de) 2004-11-11
PL331236A1 (en) 1999-07-05
HU0500910D0 (en) 2005-11-28
UA70914C2 (uk) 2004-11-15
CO4700306A1 (es) 1998-12-29
WO1998003200A3 (fr) 1998-02-26
RU2305560C2 (ru) 2007-09-10
HRP970383A2 (en) 1998-10-31
DE69734483D1 (de) 2005-12-01
US6376473B1 (en) 2002-04-23
CZ298915B6 (cs) 2008-03-12
CA2260855C (en) 2012-01-03
MA24269A1 (fr) 1998-04-01
ATE253376T1 (de) 2003-11-15
EP1382348A3 (fr) 2004-01-28
AU3773597A (en) 1998-02-10
EP0912194A2 (fr) 1999-05-06
NZ508939A (en) 2002-04-26
FR2751229A1 (fr) 1998-01-23
DE69734483T2 (de) 2006-07-20
CZ298898B6 (cs) 2008-03-05
IL127703A (en) 2006-12-31
CA2260855A1 (en) 1998-01-29
HUP9902791A3 (en) 2000-03-28
IL127703A0 (en) 1999-10-28
US6818628B2 (en) 2004-11-16
HUP9902791A2 (hu) 1999-12-28
EP0912194B1 (fr) 2003-11-05
PL190122B1 (pl) 2005-11-30
NZ517686A (en) 2003-01-31
AR007862A1 (es) 1999-11-24
ATE307607T1 (de) 2005-11-15
DK1382348T3 (da) 2006-03-13
NZ508940A (en) 2002-09-27
FR2751229B1 (fr) 1998-11-27
CZ17599A3 (cs) 1999-06-16
PT912194E (pt) 2004-03-31
ES2210548T3 (es) 2004-07-01
WO1998003200A2 (fr) 1998-01-29
NZ333751A (en) 2001-03-30
ID19513A (id) 1998-07-16
AU734442B2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
PE84699A1 (es) Formula de vacuna polinucleotidica especialmente contra la patologia respiratoria de los bovinos
ES2232876T3 (es) Formula de vacuna polinucleotidica aviar.
AR007864A1 (es) Formula de vacuna porcina, su utilizacion y kit de vacunacion que la contiene.
ES2059370T3 (es) Un virus herpes simplex recombinante, vacunas y metodos.
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
WO2003003941A3 (en) One dose vaccination with mycoplasma hyopneumoniae
ES2066842T3 (es) Virus recombinante de la enfermedad de marek y vacuna.
ES2195998T3 (es) Sistemas de expresion de dna basados en alfavirus.
BR0211474A (pt) Uso de tat de hiv-1 biologicamente ativa, fragmentos ou derivadas desta, para atingir e/ou ativar células apresentadoras de antìgeno, e/ou para disponibilizar moléculas carga para vacinação e/ou tratamento preventivo ou terapêutico de outras doenças
AR009947A1 (es) COMPOSICIoN DE VACUNA PARA EQUIDOS QUE COMPRENDEN TAMBIEN UN VEHíCULO DE VACUNACIoN.
CO4700303A1 (es) Vacuna viva recombinante aviaria que utiliza como vector el virus de la laringotraqueitis infecciosa aviaria
BRPI0408779A (pt) uso de composições, composição imunogênica e kit
JP2008528020A (ja) 核酸構築物
AR024771A1 (es) Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
Moennig et al. Prolonged persistence of cytopathogenic bovine viral diarrhea virus (BVDV) in a persistently viremic cattle
ES2061165T3 (es) Vacuna para la proteccion de las aves de corral frente a la enfermedad de marek.
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
ES2058116T3 (es) El virus varicella-zoster como una vacuna recombinante viva.
ECSP972185A (es) Formula de vacuna polinucleotidica de bovinos particularmente contra la patologia respiratoria
WO2001082973A3 (en) Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
Marges et al. IV. PSICOBIOLOGÍA DE LA CONDUCTA ANTISOCIAL
Becker Is hepatitis B virus DNA in the dane particles a partial virus genome resembling escaping genes?
Steele Problemas de la lucha contra la rabia
ES2364466T3 (es) Vacunas de adn optimizadas por codón rt-nef-gaf para vih.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal